diflorasone diacetate


Also found in: Wikipedia.

diflorasone diacetate

[dīflôr′əsōn dī·as′ətāt]
a topical corticosteroid with high potency.
indication It is prescribed for the treatment of skin inflammation.
contraindications Viral and fungal diseases of the skin, impaired circulation, or known hypersensitivity to this drug or to other steroidal medication prohibits its use.
adverse effects Among the more serious adverse reactions, usually occurring after prolonged or excessive application, are striae, hypopigmentation, local irritation of the skin, and various systemic effects.

diflorasone diacetate

(dif´lorəsōn dīas´ətāt),
n brand names: Florone, Maxiflor, Psorcon;
drug class: topical corticosteroid, group II high potency;
action: possesses antipruritic, antiinflammatory actions;
uses: psoriasis, eczema, contact dermatitis, pruritus.

diflorasone diacetate

a corticosteroid used topically in treatment of inflammatory skin diseases.
References in periodicals archive ?
Very High Potency Augmented betamethasone dipropionate Clobetasol propionate Diflorasone diacetate Halobetasol propionate II.
TARC and RANTES, but not CTACK, are induced in two models of allergic contact dermatitis: effects of cilomilast and diflorasone diacetate on T-cell-attracting chemokines.
Other products that were cleared for marketing in 1999 include diflorasone diacetate ointment USP 0.
Food and Drug Administration (FDA) approving its Abbreviated New Drug Application (ANDA) for Diflorasone Diacetate Cream USP, 0.
The lesion gradually resolved after several weeks of treatment with topical diflorasone diacetate, Several months later the patient dyed the hair around her forehead and developed an erythematous pruritic eruption reminiscent of her reaction to the henna tattoo.
A new dosage form of di-florasone diacetate joins Fougera's diflorasone diacetate cream USP, which was introduced one year ago.
The topical products were Diflorasone Diacetate Cream, bioequivalent to Dermik Laboratories' Psorcon(R) Cream, with a U.
New product introductions in the last two years have been a main driver of Taro's growth, with a number of drugs getting FDA clearance in just the past 12 months, including the topical corticosteroids diflorasone diacetate ointment (the generic equivalent of Dermik Laboratories Inc.
Taro also received ANDA approval for Diflorasone Diacetate Cream, all three strengths of Clorazepate Dipotassium Tablets, all four strengths of Nortriptyline Hydrochloride Capsules, and Clobetasol Emollient Cream, as well as a supplemental ANDA approval for an additional strength of Etodolac Tablets.
Last year it debuted desoximetasone ointment, diflorasone diacetate cream USP, hydrocortisone scalp liquid and hydrocortisone 1% lotion.
During the second quarter of 2000, Taro received FDA approval for its New Drug Application for Clotrimazole 3-Day Vaginal Cream, its ANDAs for Diflorasone Diacetate Cream, Clorazepate Dipotassium Tablets, Nortriptyline Hydrochloride Capsules, and Clobetasol E Cream, as well as a supplemental ANDA approval for an additional strength of Etodolac Tablets.
Among the latest abbreviated new drug applications for which Fougera has received approval from the Food and Drug Administration is diflorasone diacetate cream, which is equivalent to Dermik Laboratories Inc.